Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension

This study is currently recruiting participants.
Verified May 2013 by Shire Development LLC
Sponsor:
Information provided by (Responsible Party):
Shire Development LLC
ClinicalTrials.gov Identifier:
NCT01518946
First received: January 18, 2012
Last updated: May 30, 2013
Last verified: May 2013
  Purpose

The purpose of this study is to determine whether midodrine works against the symptoms of orthostatic hypotension caused by being on a tilt table.


Condition Intervention Phase
Orthostatic Hypotension
Drug: Midodrine HCl
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 4, Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects With Symptomatic Orthostatic Hypotension

Resource links provided by NLM:


Further study details as provided by Shire Development LLC:

Primary Outcome Measures:
  • Time to onset of syncope/near syncope while on tilt table [ Time Frame: 1 hour post-dose ] [ Designated as safety issue: No ]

Estimated Enrollment: 18
Study Start Date: May 2012
Estimated Study Completion Date: May 2014
Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Midodrine HCl Drug: Midodrine HCl
dose at the subject's current dose level
Other Name: ProAmatine®
Placebo Comparator: Placebo Drug: Placebo
single dose of matching placebo

Detailed Description:

The efficacy of midodrine will be assessed in those subjects who have severe symptoms of orthostatic hypotension when not taking midodrine and are controlled when taking midodrine. The study will involve approximately 4 overnight stays.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects must be 18 years of age or older and ambulatory.
  2. Females of child-bearing potential (FOCP) must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test.
  3. A documented history of severe Symptomatic Orthostatic Hypotension (SOH) that, in the judgment of the treating physician, has required treatment with midodrine HCl , and has been at a stable dose for at least 3 months.
  4. The subject has manifested at least 1 of the following symptoms while standing or had a medical history of 1 of the following when not treated for orthostatic hypotension (OH): dizziness, lightheadedness, feeling faint, or feeling like they might black out.

Exclusion Criteria:

  1. The subject is a pregnant or lactating female.
  2. The subject has pre-existing sustained supine hypertension greater than 180mmHg systolic and 110mmHg diastolic BP or had these measurements at the Screening Visit. Sustained is defined as persistently greater at 2 separate measurements at least 5 minutes apart with the subject supine and at rest for the 5 minutes.
  3. Subjects taking concomitant medications of interest are excluded unless those medications are reviewed and discussed with the Medical Monitor or Study Physician and documented prior to enrolling the subject. If agreement is reached between the Investigator and Sponsor for the subject to continue in the study, all allowed medications should be maintained at a constant dose throughout the study.
  4. The Principal Investigator deems any clinical laboratory test (at the Screening Visit) abnormality to be clinically significant
  5. The subject has participated in other studies of investigational drugs or devices within 30 days prior to enrollment in this study (other than Study SPD426-406).
  6. Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures.
  7. The subject has a concurrent chronic or acute illness, disability, or other condition (including significant unexpected laboratory or electrocardiogram [ECG] findings) that might confound the results of the tests and/or measurements administered in this study, or that might have increased the risk to the subject.
  8. Known or suspected intolerance or hypersensitivity to the investigational product(s), closely-related compounds, or any of the stated ingredients.
  9. Prior enrollment failure or randomization in this study.
  10. History of alcohol abuse or other substance abuse within the last year.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01518946

Contacts
Contact: Shire Call Center +1 866-842-5335

Locations
United States, Florida
Parkinson's Disease and Movement Disorders Center of Boca Raton Not yet recruiting
Boca Raton, Florida, United States, 33486
Contact: Ann Diaz     561-392-1818        
Contact: Jenifer Bar-Nur     561-392-1818        
Principal Investigator: Stuart Isaacson            
Advance Research Institute Inc Not yet recruiting
New Port Richey, Florida, United States, 34653
Contact: Audrey Scalin     727-835-3261        
Principal Investigator: Daniel Rodriguez, MD            
United States, Kansas
Analab Clinical Research Inc Recruiting
Lenexa, Kansas, United States, 66219
Contact: Shultz     913-221-0421 ext 350     rshultz@analabcr.com    
Principal Investigator: Stephen Maddock, MD, PhD            
United States, Minnesota
Mayo Clinic Not yet recruiting
Rochester, Minnesota, United States, 55905
Contact: James Schmelzer     507-284-0002        
Principal Investigator: Phillip Low            
United States, New York
Buffalo Clinical Research Center (BCRC) Not yet recruiting
Buffalo, New York, United States, 14202
Contact: Robert Blum     716-885-3580        
Principal Investigator: Christen Lates            
Columbia University Not yet recruiting
New York, New York, United States, 10032
Contact: Stacy Mano     212-305-6035        
Principal Investigator: Louis Weimer            
NYU Medical Centre Active, not recruiting
New York, New York, United States, 10016
United States, Ohio
Cleveland Clinic Not yet recruiting
Cleveland, Ohio, United States, 44195
Contact: Raquel Rozick     216-444-4959        
Principal Investigator: Fetnat Fouad-Tarazi            
United States, Oregon
Kidney and Hypertension Center Not yet recruiting
Roseburg, Oregon, United States, 97471
Contact: Lori Romero     541-957-1133        
Principal Investigator: Neil Kumar            
United States, Tennessee
New Orleans Center for Clinical Research - Knoxville Recruiting
Knoxville, Tennessee, United States, 37920
Principal Investigator: William B Smith, M.D            
United States, Texas
The Heartbeat Clinic, PA Recruiting
McKinney, Texas, United States, 75069
Contact: Alice Young     214-843-2298     ayoung@ntmtrials.net    
Principal Investigator: Amer Suleman            
United States, Utah
Aspen Clinical Research Recruiting
Orem, Utah, United States, 84058
Contact: Ian Dawe     801-342-5409     iand@aspenclinicalresearch.com    
Principal Investigator: Aaron Weaver, M.D            
United States, Wisconsin
Aurora Cardiovascular Services Not yet recruiting
Milwaukee, Wisconsin, United States, 53215
Contact: Anthony Chambers     414-385-2565        
Principal Investigator: Ryan Cooley            
Sponsors and Collaborators
Shire Development LLC
  More Information

No publications provided

Responsible Party: Shire Development LLC
ClinicalTrials.gov Identifier: NCT01518946     History of Changes
Other Study ID Numbers: SPD426-406
Study First Received: January 18, 2012
Last Updated: May 30, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Shire Development LLC:
Symptomatic Orthostatic Hypotension

Additional relevant MeSH terms:
Hypotension
Hypotension, Orthostatic
Vascular Diseases
Cardiovascular Diseases
Orthostatic Intolerance
Primary Dysautonomias
Autonomic Nervous System Diseases
Nervous System Diseases
Midodrine
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Adrenergic alpha-1 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 17, 2013